PROFESSOR LIANG CHENG’S BIOGRAPHICAL SUMMARY
Dr. Liang Cheng is the Professor of Pathology and Surgery/Urology (Research Scholar Track), Vice Chair for Translational Research, Director of Anatomic Pathology, Director of Molecular Pathology in the Department of Pathology and Laboratory Medicine at the Brown University Warren Alpert Medical School | Brown University Health. He is also the Associate Director for Shared Resources, the Legorreta Cancer Center at Brown University, Providence, Rhode Island. Dr. Cheng has published over 1,200 peer-reviewed SCI articles (citations, 72,508; h-index: 133; i10-index: 964) in high-impact scientific journals, including British Medical Journal (BMJ) (IF 107), Nature Reviews Disease Primers (IF 81), Nature Biotechnology (IF 68), Cancer Cell (IF 50), Annals of Oncology (IF 56), Journal of Clinical Oncology (IF 50), JAMA Oncology (IF 32), Molecular Cancer (IF 41), Cell Metabolism (IF 31), Gut (IF 31), Science Immunology (IF 30). Dr. Cheng is the author of over 150 book chapters and 20 textbooks, including Urologic Surgical Pathology, Tumors of the Kidney, Bladder, and Related Urinary Structures (AFIP Fascicle, 5th Series), Molecular Genetic Pathology, Molecular Surgical Pathology, Essentials of Anatomic Pathology, Bladder Pathology and others. Dr. Cheng is ranked among the top three most cited authors in the category of “Urologic Oncology” and “Urology” in Google Scholar. Currently, he is an active member of over 30 Editorial Boards, and the Editor-in-Chief of two major journals: Expert Review of Precision Medicine and Drug Development and American Journal of Translational Research. Dr. Cheng received the Arthur Purdy Stout Annual Award from the Society of Surgical Pathologists in recognition of his outstanding contributions to the field of surgical pathology. He also received the Koss Medal Award, the highest award bestowed by the International Society of Urological Pathology (ISUP) for his lifetime achievement in urological pathology. Dr. Cheng is the President-Elect (2023-2025) of the International Society of Urological Pathology (ISUP). Dr. Cheng's research focuses on translational studies of genitourinary cancers and molecular diagnostics of solid tumors (Email: liang_cheng@brown.edu | website: https://vivo.brown.edu/display/lcheng26).
Contact Information:
Liang Cheng, M.D., M.S.
Professor of Pathology and Surgery/Urology
Vice Chair for Translational Research
Director of Anatomic Pathology
Director of Molecular Pathology
Department of Pathology and Laboratory Medicine
Warren Alpert Medical School of Brown University | Brown University Health
Associate Director for Shared Resources
Legorreta Cancer Center at Brown University
Address: 593 Eddy Street, APC 12-105 | Providence, RI 02903
Tel: 401-606-4654 | Fax: 401-606-2361 | Twitter: @LiangChengMD
E-mail: liang_cheng@yahoo.com or liang_cheng@brown.edu
Faculty Profile: https://vivo.brown.edu/display/lcheng26
President-Elect, International Society of Urological Pathology (ISUP)
Editor-in-Chief, American Journal of Translational Research
Editor-in-Chief, Expert Review of Precision Medicine & Drug Development
BIOGRAPHICAL SKETCH
Dr. Liang Cheng is the Professor of Pathology and Surgery/Urology (Research Scholar Track), Vice Chair for Translational Research, Director of Anatomic Pathology, Director of Molecular Pathology in the Department of Pathology and Laboratory Medicine at the Brown University Warren Alpert Medical School | Brown University Health. He is also the Associate Director for Shared Resources, the Legorreta Cancer Center at Brown University, Providence, Rhode Island. He served for over a decade as the inaugural Virgil H. Moon Endowed Chair Professor of Pathology, Professor of Urology; Director of Molecular Pathology Laboratories, and Director of Genitourinary Pathology at Indiana University School of Medicine | Indiana University Health, Indianapolis, Indiana.
Dr. Cheng is board certified in Molecular Genetic Pathology, Anatomic and Clinical Pathology by the American Board of Pathology. At the age of 15, he entered the six-year medical program in Beijing Medical University/Peking University (the top medical school in China) as the youngest medical student. Dr. Cheng completed his pathology residency at Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio and his fellowship at the Mayo Clinic, Rochester, Minnesota. Dr. Cheng has received numerous prestigious awards including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology (USCAP) and the Koss Medal Award from the International Society of Urological Pathology (ISUP) (“The medal is awarded for a lifetime achievement in the broad field of urological pathology and is the highest award bestowed by the Society”). He was the recipient of the annual Arthur Purdy Stout Prize from the Arthur Purdy Stout Society of Surgical Pathologists in recognition of outstanding contributions to the field of surgical pathology as a surgical pathologist under the age of 45. He also received the W. Dwayne Lawrence Award for Excellence in Diagnostic Surgical Pathology. Dr. Cheng was the Chairperson for the International Society of Urological Pathology (ISUP) Bladder Cancer Grading Working Group in 2020 (the work was published in European Urology Focus 2021 PMID: 33771477). He was also the Chairperson for ISUP Molecular Pathology of Bladder Cancer Working Group in 2019 (the work was published in American Journal of Surgical Pathology 2019 PMID:32091435); Chairperson for 2022 ISUP Multidisciplinary Consensus Conference on Current Issues in Bladder Cancer in Basel, Switzerland (the work was published in American Journal of Surgical Pathology 2024 PMID: 37288838); and Conference Chairperson for 2024 ISUP Multidisciplinary Consensus Conference on Cancer Precursor Lesions of the Genitourinary Organs in Florence, Italy. He is the current President-Elect (2023-2025) of the International Society of Urological Pathology (https://isupweb.org). Dr. Cheng was the Chair of the American Society of Clinical Oncology (ASCO) Education Program on “Applications of Artificial Intelligence in Prostate Cancer Care” at the 2024 ASCO Annual Meeting in Chicago.
Dr. Cheng has published over 1,200 peer-reviewed articles in high-impact scientific journals, including British Medical Journal (BMJ) (IF 107), Nature Reviews Disease Primers (IF 81), Nature Biotechnology (IF 68), Cancer Cell (IF 50), Annals of Oncology (IF 56), Journal of Clinical Oncology (IF 50), JAMA Oncology (IF 32), Molecular Cancer (IF 41), Cell Metabolism (IF 31), Gut (IF 31), Science Immunology (IF 30), European Urology (IF 25), Cancer Communications (IF 20), Molecular Cell (IF 18), Nature Communications (IF 17), Cell Reports Medicine (IF 17), Advanced Science (IF 16), Nature Reviews Urology (IF 16), Journal of National Cancer Institute (IF 13), Proceedings of the National Academy of Science (IF 12), Clinical Cancer Research (IF 12), Cancer Research (IF 12), Molecular Therapy (IF 12), Cancer Treatment Reviews (IF 12), Theranostics (IF 12), Journal of Nanobiotechnology (IF 11), IEEE Transactions on Medical Imaging (IF 11), Endocrine Pathology (IF 11), NPJ Precision Oncology (IF 10), Cell Death and Disease (IF 10), Journal of Pathology (IF 10), as well as 61 first-author original research studies in Cancer: An Official Journal of the American Cancer Society (IF 6.8) (https://tinyurl.com/LiangChengPubMed). His published work has been cited over 72,000 times (ISI Web of Science h-index: 133; i10-index: 963). Dr. Cheng is ranked among the top three most cited authors in the category of “Urologic Oncology” and “Urology” in Google Scholar (https://tinyurl.com/LiangChengGoogleScholar). The majority of his papers are co-authored with trainees. He is an active member of over 30 editorial boards, including Molecular Cancer (IF 41, Associate Editor), Human Pathology (Senior Associate Editor), Pathology-Research and Practice (North American Editor), Applied Immunohistochemistry and Molecular Morphology (Associate Editor), Frontiers in Oncology (Associate Editor), Journal of Personalized Medicine (Section Editor-in-Chief), American Journal of Surgical Pathology, Modern Pathology, Histopathology, Virchows Archiv, Journal of Pathology (past), Expert Review of Molecular Diagnostics, European Journal of Cancer (past), Journal of Clinical Pathology, Pathology, Future Oncology, Urologic Oncology, Expert Review of Anticancer Therapy, Critical Reviews in Oncology/Hematology (past), Journal of Personalized Medicine, and others. He was an editorial board member of European Journal of Cancer, Journal of Pathology, Critical Reviews in Oncology/Hematology. He is currently the Editor-in-Chief of Expert Review of Precision Medicine and Drug Development (https://www.tandfonline.com/journals/tepm20) (2017-now). More recently, he has been appointed as the Editor-in-Chief of American Journal of Translational Research. (https://ajtr.org) Dr. Cheng was the guest editor of 2012 and 2019 Annual Review Issue (ARI) of Histopathology on Urologic Pathology. In the 2016 WHO Classification of Tumors of Urinary System and Male Genital Organ blue book, 85 of his publications, including 20 first author papers, were cited. These references accounted for 2.7% (85/3106) of the total number of referenced works. He was the author of 21 book chapters in the 2022 WHO blue book (Classification of GU Tumours). He was the first prize winner of the poster award at the 2012 European Congress of Pathology. He also established a record for the greatest number of abstract presentations (n=36) at one national meeting of the United States and Canadian Academy of Pathology (USCAP) in its history. These abstracts accounted for 2.3% (36/1551) of the total number of abstracts accepted for the 2004 annual meeting in Vancouver. Dr. Cheng was ranked No. 11 among pathologists for the total number of abstracts presented at the USCAP Annual Meetings between 2015 and 2018 (https://thepathologist.com/outside-the-lab/the-best-metric-of-success)
Dr. Cheng is also the author of over 150 book chapters and 20 textbooks, including Molecular Genetic Pathology (Springer Nature, 2008 and 2013), Molecular Surgical Pathology (Springer Nature, 2013 and 2023), Bladder Pathology (Wiley, 2012 and 2022), Urologic Surgical Pathology (Elsevier, 2008, 2014, 2020, 2025), Essentials of Anatomic Pathology (Springer Nature, 2002, 2006, 2011, and 2016), Pathology of the Prostate (Cambridge University Press, 2017), Atlas of Anatomic Pathology (Series Editor, Springer, 2011-present), and Tumors of the Kidney, Bladder, and Related Urinary Structures (Armed Forces Institute of Pathology /AFIP Fascicle, 5th Series. ARP Press, 2022). His textbook, Essentials of Anatomic Pathology, which is now in its 4th edition, is the No. 1 downloaded book from Springer, and has been downloaded 210,812 times since its online publication on April 5, 2011. He is the chief editor of the classical urologic textbook, Urologic Surgical Pathology (Elsevier, 4th edition, 2020), which is ranked as the No. 1 new book release from both Pathology and Urology categories in Amazon. His 2023 new book, Molecular Surgical Pathology, is ranked as as the No. 1 new book release from Oncology category, and the No. 4 from Pathology category in Amazon.
Under Dr. Cheng’s Directorship at Indiana University, the annual volume of molecular tests performed at the IU Health Molecular Pathology Laboratory has increased 7.3-fold from 31,418 molecular tests in 2007 to 230,531 tests in 2017. Dr. Cheng is also the principal or co-investigator for more than 40 funded grants and has served as a member of over 50 Grant Review Panels for Federal Funding Agencies (NIH, NCI, DOD, etc.). He has served as an NIH/NCI review panelist for the Specialized Programs of Research Excellence (SPORE) each year since 2000. Dr. Cheng has been a member of the National Cancer Institute Bladder Cancer Task Force and the Surgical Pathology Committee of the College of American Pathologist (CAP), and an author and a member of the CAP Cancer Panel Working Group for the Cancer Genomics Resource (2014). He has been an author and member of the international working groups for the 2004, 2016 and 2022 WHO Blue Books on Tumors of the Urinary System and Male Genital Organs. In 2021, Dr. Cheng was ranked No. 1 among the World’s Experts in Urogenital Neoplasms (https://expertscape.com/ex/urologic+neoplasms) and Top 3 Experts in the field of Bladder Cancer by Expertscape (https://expertscape.com/ex/bladder+cancer). Dr. Cheng's research focuses on translational studies of genitourinary cancers and molecular diagnostics of solid tumors (website: https://vivo.brown.edu/display/lcheng26).
Full CV available upon request:
Liang Cheng, MD, MS
Department of Pathology
593 Eddy Street, APC 12-105
Providence, RI 02903
Tel: 1-401-606-4654; Fax: 1-401-606-2361
E-mail: liang_cheng@yahoo.com or liang_cheng@brown.edu
